Silexion Therapeutics Corp (NASDAQ:SLXN)
| Market Cap | 149.71K-99.3% |
| Revenue (ttm) | 0 |
| Net Income | -13.96M+21.7% |
| EPS | -56.54+98.1% |
| Shares Out | 419.00K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,517,903 |
| Open | 0.36 |
| Previous Close | 0.42 |
| Day's Range | 0.34 - 0.39 |
| 52-Week Range | 0.34 - 46.94 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About SLXN
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SLXN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SLXN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SLXN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SLXN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SLXN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Segment liabilities | $4.20M | 84.21% |
| Professional services | $788.00K | 15.79% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SLXN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SLXN from public contracts
Source: USAspending.gov
SLXN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SLXN’s recent data — informational, not investment advice